한글목차

폐동맥 고혈압(PAH) 치료제 시장은 2023-2028년 22억 6,470만 달러로 예측되며, 예측 기간 동안 6.78%의 CAGR로 성장할 것으로 예상됩니다. 폐동맥 고혈압(PAH) 치료제 시장에 대해 조사 분석했으며, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더에 대한 벤더 분석 등의 정보를 전해드립니다.

현재 시장 시나리오, 최신 동향 및 촉진요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 시장은 PAH의 유병률 증가, 노인 인구 증가, 심혈관질환의 위험 요소 증가에 의해 주도되고 있습니다.

이 보고서는 향후 몇 년간 폐동맥 고혈압(PAH) 치료제 시장 성장을 주도할 주요 요인 중 하나로 PAH에 대한 인식이 높아지는 것을 꼽았습니다. 또한, 기술 발전과 신제품 출시, PAH 치료제의 승인 증가는 시장 수요를 증가시킬 것으로 예상됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 상황

• 시장 생태계
• 시장의 특징
• 밸류체인 분석

제3장 시장 규모 평가

• 시장 정의
• 시장 부문 분석
• 시장 규모 2023년
• 시장 전망 2023-2028년

제4장 시장 규모 실적

• 폐동맥 고혈압(PAH) 치료제 세계 시장 2018-2022년
• 투여 경로별 부문 분석 2018-2022년
• 작용기서별 부문 분석 2018-2022년
• 지역별 부문 분석 2018-2022년
• 국가별 부문 분석 2018-2022년

제5장 Five Forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 참여업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 상황

제6장 시장 세분화 : 투여 경로별

• 시장 세분화
• 비교 : 투여 경로별
• 경구 : 시장 규모와 예측 2023-2028년
• 주사 : 시장 규모와 예측 2023-2028년
• 흡입 : 시장 규모와 예측 2023-2028년
• 시장 기회 : 투여 경로별

제7장 시장 세분화 : 작용기서별

• 시장 세분화
• 비교 : 작용기서별
• 프로스타사이클린 유사체 : 시장 규모와 예측 2023-2028년
• 엔도텔린 수용체 길항제(ERA) : 시장 규모와 예측 2023-2028년
• 포스포디에스테라제(PDE) 억제제 : 시장 규모와 예측 2023-2028년
• 가용성 구아닐레이트 사이클레이즈 자극제(SGCS) : 시장 규모와 예측 2023-2028년
• 시장 기회 : 작용기서별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 비교 : 지역별
• 북미 : 시장 규모와 예측 2023-2028년
• 유럽 : 시장 규모와 예측 2023-2028년
• 아시아 : 시장 규모와 예측 2023-2028년
• 기타 : 시장 규모와 예측 2023-2028년
• 미국 : 시장 규모와 예측 2023-2028년
• 영국 : 시장 규모와 예측 2023-2028년
• 독일 : 시장 규모와 예측 2023-2028년
• 캐나다 : 시장 규모와 예측 2023-2028년
• 일본 : 시장 규모와 예측 2023-2028년
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제, 기회, 억제요인

• 시장 성장 촉진요인
• 시장 과제
• 성장 촉진요인과 과제의 영향
• 시장 기회·억제요인

제11장 경쟁 상황

• 개요
• 경쟁 상황
• 혼란 상황
• 업계 리스크

제12장 경쟁 분석

• 기업 개요
• 기업의 시장 포지셔닝
• Aerami Therapeutics Holdings Inc.
• Asklepion Pharmaceuticals LLC
• AstraZeneca Plc
• Bayer AG
• Daiichi Sankyo Co. Ltd.
• Eiger BioPharmaceuticals Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corp.

제13장 부록

영문목차

The pulmonary arterial hypertension (PAH) drugs market is forecasted to grow by USD 2264.7 mn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the pulmonary arterial hypertension (PAH) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of PAH, growing geriatric population, and increasing risk factors for cardiovascular diseases.

Technavio's pulmonary arterial hypertension (PAH) drugs market is segmented as below:

By Route Of Administration

• Oral
• Injectable
• Inhalation

By Action Mechanism

• Prostacyclin analogs
• Endothelin receptor antagonists (ERAs)
• Phosphodiesterase (PDE) inhibitors
• Soluble guanylate cyclase stimulators (SGCSs)

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing awareness regarding PAH as one of the prime reasons driving the pulmonary arterial hypertension (PAH) drugs market growth during the next few years. Also, growing technological advancements and new product launches and rising approval of PAH drugs will lead to sizable demand in the market.

The report on the pulmonary arterial hypertension (PAH) drugs market covers the following areas:

• Pulmonary arterial hypertension (PAH) drugs market sizing
• Pulmonary arterial hypertension (PAH) drugs market forecast
• Pulmonary arterial hypertension (PAH) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary arterial hypertension (PAH) drugs market vendors that include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca PLC, Bayer AG, Daiichi Sankyo Co. Ltd., DR Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc.. Also, the pulmonary arterial hypertension (PAH) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Action Mechanism
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 2.2 Market characteristics
  • Market characteristics analysis
• 2.3 Value chain analysis
  • Value Chain Analysis

3 Market Sizing

• 3.1 Market definition
  • Offerings of companies included in the market definition
• 3.2 Market segment analysis
  • Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
  • Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2018 - 2022
  • Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2018 - 2022 ($ million)
• 4.2 Route of Administration segment analysis 2018 - 2022
  • Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• 4.3 Action Mechanism segment analysis 2018 - 2022
  • Historic Market Size - Action Mechanism Segment 2018 - 2022 ($ million)
• 4.4 Geography segment analysis 2018 - 2022
  • Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country segment analysis 2018 - 2022
  • Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
  • Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

• 6.1 Market segments
  • Chart on Route of Administration - Market share 2023-2028 (%)
  • Data Table on Route of Administration - Market share 2023-2028 (%)
• 6.2 Comparison by Route of Administration
  • Chart on Comparison by Route of Administration
  • Data Table on Comparison by Route of Administration
• 6.3 Oral - Market size and forecast 2023-2028
  • Chart on Oral - Market size and forecast 2023-2028 ($ million)
  • Data Table on Oral - Market size and forecast 2023-2028 ($ million)
  • Chart on Oral - Year-over-year growth 2023-2028 (%)
  • Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 6.4 Injectable - Market size and forecast 2023-2028
  • Chart on Injectable - Market size and forecast 2023-2028 ($ million)
  • Data Table on Injectable - Market size and forecast 2023-2028 ($ million)
  • Chart on Injectable - Year-over-year growth 2023-2028 (%)
  • Data Table on Injectable - Year-over-year growth 2023-2028 (%)
• 6.5 Inhalation - Market size and forecast 2023-2028
  • Chart on Inhalation - Market size and forecast 2023-2028 ($ million)
  • Data Table on Inhalation - Market size and forecast 2023-2028 ($ million)
  • Chart on Inhalation - Year-over-year growth 2023-2028 (%)
  • Data Table on Inhalation - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)
  • Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Action Mechanism

• 7.1 Market segments
  • Chart on Action Mechanism - Market share 2023-2028 (%)
  • Data Table on Action Mechanism - Market share 2023-2028 (%)
• 7.2 Comparison by Action Mechanism
  • Chart on Comparison by Action Mechanism
  • Data Table on Comparison by Action Mechanism
• 7.3 Prostacyclin analogs - Market size and forecast 2023-2028
  • Chart on Prostacyclin analogs - Market size and forecast 2023-2028 ($ million)
  • Data Table on Prostacyclin analogs - Market size and forecast 2023-2028 ($ million)
  • Chart on Prostacyclin analogs - Year-over-year growth 2023-2028 (%)
  • Data Table on Prostacyclin analogs - Year-over-year growth 2023-2028 (%)
• 7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028
  • Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028 ($ million)
  • Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2023-2028 ($ million)
  • Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2023-2028 (%)
  • Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2023-2028 (%)
• 7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028
  • Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028 ($ million)
  • Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2023-2028 ($ million)
  • Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2023-2028 (%)
  • Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2023-2028 (%)
• 7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028
  • Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028 ($ million)
  • Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2023-2028 ($ million)
  • Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2023-2028 (%)
  • Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2023-2028 (%)
• 7.7 Market opportunity by Action Mechanism
  • Market opportunity by Action Mechanism ($ million)
  • Data Table on Market opportunity by Action Mechanism ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
  • Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Chart on North America - Year-over-year growth 2023-2028 (%)
  • Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
  • Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
  • Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
  • Chart on US - Market size and forecast 2023-2028 ($ million)
  • Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Chart on US - Year-over-year growth 2023-2028 (%)
  • Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 UK - Market size and forecast 2023-2028
  • Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Chart on UK - Year-over-year growth 2023-2028 (%)
  • Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
  • Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 Canada - Market size and forecast 2023-2028
  • Chart on Canada - Market size and forecast 2023-2028 ($ million)
  • Data Table on Canada - Market size and forecast 2023-2028 ($ million)
  • Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.11 Japan - Market size and forecast 2023-2028
  • Chart on Japan - Market size and forecast 2023-2028 ($ million)
  • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
  • Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Opportunity/Restraints

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2023 and 2028
• 10.4 Market opportunities/restraints

11 Competitive Landscape

• 11.1 Overview
• 11.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 11.3 Landscape disruption
  • Overview on factors of disruption
• 11.4 Industry risks
  • Impact of key risks on business

12 Competitive Analysis

• 12.1 Companies profiled
  • Companies covered
• 12.2 Market positioning of companies
  • Matrix on companies position and classification
• 12.3 Aerami Therapeutics Holdings Inc.
  • Aerami Therapeutics Holdings Inc. - Overview
  • Aerami Therapeutics Holdings Inc. - Product / Service
  • Aerami Therapeutics Holdings Inc. - Key offerings
• 12.4 Asklepion Pharmaceuticals LLC
  • Asklepion Pharmaceuticals LLC - Overview
  • Asklepion Pharmaceuticals LLC - Product / Service
  • Asklepion Pharmaceuticals LLC - Key offerings
• 12.5 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
• 12.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
• 12.7 Daiichi Sankyo Co. Ltd.
  • Daiichi Sankyo Co. Ltd. - Overview
  • Daiichi Sankyo Co. Ltd. - Product / Service
  • Daiichi Sankyo Co. Ltd. - Key news
  • Daiichi Sankyo Co. Ltd. - Key offerings
• 12.8 Eiger BioPharmaceuticals Inc.
  • Eiger BioPharmaceuticals Inc. - Overview
  • Eiger BioPharmaceuticals Inc. - Product / Service
  • Eiger BioPharmaceuticals Inc. - Key offerings
• 12.9 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Product / Service
  • Gilead Sciences Inc. - Key news
  • Gilead Sciences Inc. - Key offerings
• 12.10 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
• 12.11 Johnson and Johnson Services Inc.
  • Johnson and Johnson Services Inc. - Overview
  • Johnson and Johnson Services Inc. - Business segments
  • Johnson and Johnson Services Inc. - Key news
  • Johnson and Johnson Services Inc. - Key offerings
  • Johnson and Johnson Services Inc. - Segment focus
• 12.12 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Product / Service
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
• 12.13 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
• 12.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
• 12.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. - Overview
  • Teva Pharmaceutical Industries Ltd. - Business segments
  • Teva Pharmaceutical Industries Ltd. - Key news
  • Teva Pharmaceutical Industries Ltd. - Key offerings
  • Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 United Therapeutics Corp.
  • United Therapeutics Corp. - Overview
  • United Therapeutics Corp. - Product / Service
  • United Therapeutics Corp. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 13.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 13.4 Research methodology
  • Research methodology
• 13.5 Data procurement
  • Information sources
• 13.6 Data validation
  • Data validation
• 13.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 13.8 Data synthesis
  • Data synthesis
  • 360 degree market analysis
  • 360 degree market analysis
• 13.10 List of abbreviations
  • List of abbreviations